Your browser doesn't support javascript.
SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine.
Giménez, Estela; Albert, Eliseo; Burgos, Javier S; Peiró, Salvador; Salas, Dolores; Vanaclocha, Hermelinda; Limón, Ramón; Alcaraz, María Jesús; Sánchez-Payá, José; Díez-Domingo, Javier; Comas, Iñaki; Gonzáles-Candelas, Fernando.
  • Giménez E; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Albert E; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Burgos JS; General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain.
  • Peiró S; Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
  • Salas D; Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain; General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
  • Vanaclocha H; General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain.
  • Limón R; General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain.
  • Alcaraz MJ; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Sánchez-Payá J; Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain.
  • Díez-Domingo J; Foundation for the promotion of health and biomedical research of the Valencian Community (FISABIO), Valencia, Spain.
  • Comas I; Biomedicine Institute of Valencia, Spanish Research Council (CSIC).
  • Gonzáles-Candelas F; CIBER in Epidemiology and Public Health, Spain, Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain.
J Infect ; 84(6): 834-872, 2022 06.
Article in English | MEDLINE | ID: covidwho-1712811
ABSTRACT
Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice-President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló); Hernández-Aguado I (University Miguel Hernández, Alicante, Spain); Oliver Ramírez N (DataPop Alliance); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Vento Torres M (Instituto de Investigación Sanitaria La Fe); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain;Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: J Infect Year: 2022 Document Type: Article Affiliation country: J.jinf.2022.02.035

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Europa Language: English Journal: J Infect Year: 2022 Document Type: Article Affiliation country: J.jinf.2022.02.035